PL2182988T3 - Kompozycja radiofarmaceutyczna - Google Patents

Kompozycja radiofarmaceutyczna

Info

Publication number
PL2182988T3
PL2182988T3 PL08803301T PL08803301T PL2182988T3 PL 2182988 T3 PL2182988 T3 PL 2182988T3 PL 08803301 T PL08803301 T PL 08803301T PL 08803301 T PL08803301 T PL 08803301T PL 2182988 T3 PL2182988 T3 PL 2182988T3
Authority
PL
Poland
Prior art keywords
radiopharmaceutical composition
radiopharmaceutical
composition
Prior art date
Application number
PL08803301T
Other languages
English (en)
Inventor
Line Roed
Sarah Elizabeth Peterson
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of PL2182988T3 publication Critical patent/PL2182988T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08803301T 2007-08-30 2008-08-28 Kompozycja radiofarmaceutyczna PL2182988T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96890407P 2007-08-30 2007-08-30
PCT/EP2008/061275 WO2009027452A2 (en) 2007-08-30 2008-08-28 Radiopharmaceutical composition
EP08803301.4A EP2182988B1 (en) 2007-08-30 2008-08-28 Radiopharmaceutical composition

Publications (1)

Publication Number Publication Date
PL2182988T3 true PL2182988T3 (pl) 2015-02-27

Family

ID=40029249

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08803301T PL2182988T3 (pl) 2007-08-30 2008-08-28 Kompozycja radiofarmaceutyczna

Country Status (20)

Country Link
US (1) US8916131B2 (pl)
EP (1) EP2182988B1 (pl)
JP (1) JP5367708B2 (pl)
KR (1) KR101571572B1 (pl)
CN (1) CN101790387B (pl)
AU (1) AU2008292201B2 (pl)
BR (1) BRPI0815129B8 (pl)
CA (1) CA2694084C (pl)
DK (1) DK2182988T3 (pl)
ES (1) ES2464715T3 (pl)
HU (1) HUS1500007I1 (pl)
IL (1) IL203316A (pl)
MX (1) MX2010002196A (pl)
NO (1) NO2015006I1 (pl)
NZ (1) NZ583616A (pl)
PL (1) PL2182988T3 (pl)
PT (1) PT2182988E (pl)
RU (1) RU2475267C2 (pl)
WO (1) WO2009027452A2 (pl)
ZA (1) ZA201000718B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG182378A1 (en) * 2009-10-08 2012-08-30 Ge Healthcare Ltd Purification method
WO2013173004A2 (en) 2012-04-10 2013-11-21 Lantheus Medical Imaging, Inc. Radiopharmaceutical synthesis methods
WO2016087653A1 (en) 2014-12-04 2016-06-09 Ge Healthcare Limited Method of removing acetaldehyde from radioactive pharmaceuticals
JP6485914B2 (ja) 2015-10-28 2019-03-20 日本メジフィジックス株式会社 フルテメタモルの製造方法
JP6955347B2 (ja) 2017-02-28 2021-10-27 日本メジフィジックス株式会社 フルテメタモルの製造方法
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
BR112022019360A2 (pt) * 2020-03-27 2022-12-27 Jubilant Pharma Holdings Inc Sistema de dispensação de radiofármacos
KR102207372B1 (ko) * 2020-03-31 2021-01-27 재단법인 아산사회복지재단 방사성 의약품의 안정화제 및 이를 포함하는 방사성 의약 조성물
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis
US11980685B1 (en) 2022-12-23 2024-05-14 Tap Pharmaceuticals, Ag Liquid pharmaceutical formulations of tafamidis
WO2026012430A1 (zh) * 2024-07-10 2026-01-15 天津恒瑞医药有限公司 一种含有氟[18f]美他酚的药物组合物及其制备方法和医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335095A (en) * 1979-03-21 1982-06-15 The Radiochemical Centre Limited Indium-111 oxine complex composition
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
DK1334091T3 (da) * 2000-08-24 2012-10-15 Univ Pittsburgh Thioflavinderivater og deres anvendelse til diagnose og terapi af Alzheimer's sygdom
JP2005523903A (ja) * 2002-02-13 2005-08-11 アメルシャム・パブリック・リミテッド・カンパニー アミロイド斑の生体内撮像用のベンゾチアゾール誘導体
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
US20050043523A1 (en) * 2003-08-22 2005-02-24 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
JP2008505116A (ja) * 2004-07-02 2008-02-21 ユニバーシティー オブ ピッツバーグ アミロイド沈着を伴う疾患の前駆形態の診断方法
ES2427963T3 (es) 2004-07-02 2013-11-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Uso de derivados de tioflavina radiomarcados en formación de imágenes de amiloide para evaluación de las terapias antiamiloide
US20070031328A1 (en) * 2005-06-24 2007-02-08 Kung Hank F Radiolabeled-pegylation of ligands for use as imaging agents
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
AU2006320556A1 (en) * 2005-12-01 2007-06-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isotopically-labeled benzothiazole compounds as imaging agents for amyloidogenic proteins
US7858803B2 (en) 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders

Also Published As

Publication number Publication date
EP2182988B1 (en) 2014-04-16
BRPI0815129A2 (pt) 2015-02-03
CN101790387B (zh) 2013-03-20
CA2694084A1 (en) 2009-03-05
KR101571572B1 (ko) 2015-11-24
AU2008292201B2 (en) 2014-09-04
JP2010536931A (ja) 2010-12-02
RU2010101935A (ru) 2011-10-10
CA2694084C (en) 2015-07-07
MX2010002196A (es) 2010-03-18
US20110008254A1 (en) 2011-01-13
PT2182988E (pt) 2014-05-16
NO2015006I2 (no) 2015-02-18
WO2009027452A2 (en) 2009-03-05
NZ583616A (en) 2012-06-29
DK2182988T3 (da) 2014-05-26
KR20100055440A (ko) 2010-05-26
BRPI0815129B1 (pt) 2021-01-12
JP5367708B2 (ja) 2013-12-11
EP2182988A2 (en) 2010-05-12
CN101790387A (zh) 2010-07-28
WO2009027452A3 (en) 2009-09-03
US8916131B2 (en) 2014-12-23
ZA201000718B (en) 2010-10-27
AU2008292201A1 (en) 2009-03-05
BRPI0815129B8 (pt) 2021-05-25
HUS1500007I1 (hu) 2021-05-07
ES2464715T3 (es) 2014-06-03
IL203316A (en) 2015-02-26
HK1146710A1 (zh) 2011-07-08
RU2475267C2 (ru) 2013-02-20
NO2015006I1 (no) 2015-03-02

Similar Documents

Publication Publication Date Title
GB0718777D0 (en) Composition
GB0700534D0 (en) Composition
PL2118255T3 (pl) Środki czyszczące
GB0711683D0 (en) Compositions
ZA200907382B (en) Composition
GB0722550D0 (en) Composition
ZA201000718B (en) Radiopharmaceutical composition
GB0718386D0 (en) Improved radiopharmaceutical formulation
GB0714575D0 (en) Composition
GB0710888D0 (en) Composition
ZA200907615B (en) Biofertiliser composition
GB0716591D0 (en) Composition
ZA200908272B (en) Composition
GB0703719D0 (en) Composition
GB0706343D0 (en) Composition
GB0702446D0 (en) Composition
GB0707972D0 (en) Composition
GB0706739D0 (en) Composition
GB0704651D0 (en) Composition
ZA200906258B (en) Composition
GB0723825D0 (en) Composition
GB0721430D0 (en) Composition
GB0713976D0 (en) Composition
GB0710559D0 (en) Composition
GB0703087D0 (en) Composition